Nirvana Life Sciences Inc.
NIRV
CNSX
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 40.80K | 36.30K | 115.50K | 96.20K | 99.00K |
| Depreciation & Amortization | -- | -- | 4.50K | 9.00K | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.80K | 36.30K | 140.00K | 120.20K | 114.20K |
| Operating Income | -40.80K | -36.30K | -140.00K | -120.20K | -114.20K |
| Income Before Tax | -44.90K | -41.00K | -256.60K | 3.70K | -124.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.90K | -41.00K | -256.60K | 3.70K | -124.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 200.00 | 100.00 | 200.00 | 300.00 | 300.00 |
| Net Income | -44.80K | -40.90K | -256.30K | 4.00K | -124.00K |
| EBIT | -40.80K | -36.30K | -140.00K | -120.20K | -114.20K |
| EBITDA | -37.50K | -33.00K | -135.50K | -117.20K | -97.30K |
| EPS Basic | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 48.23M | 48.23M | 48.34M | 48.23M | 48.23M |
| Average Diluted Shares Outstanding | 48.23M | 48.23M | 48.34M | 48.23M | 48.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
